EADV 2026
JAK1 inhibitor versus dupilumab: relapse after discontinuation in adults with atopic dermatitis
SETTING THE SCENE Both JAK1 inhibitors and dupilumab produce impressive
Mukul Ayachit
October 15, 2026
SETTING THE SCENE Both JAK1 inhibitors and dupilumab produce impressive
SETTING THE SCENE Facial AD in children with skin of
SETTING THE SCENE The 2% crisaborole formulation is one of
A systematic review and meta-analysis presented at the 2026 ACOG
A large population-based study presented at the 2026 ACOG Scientific
A quality improvement initiative presented at the 2026 ACOG Scientific